scholarly journals In-vitro activity of quinupristin/dalfopristin (Synercid) against isolates of Streptococcus pneumoniae, Staphylococcus aureus and enterococcus spp

1997 ◽  
Vol 40 (4) ◽  
pp. 604-605 ◽  
Author(s):  
A. P. Johnson ◽  
M. Warner ◽  
D. C. Speller
2002 ◽  
Vol 46 (6) ◽  
pp. 1989-1992 ◽  
Author(s):  
James A. Karlowsky ◽  
Laurie J. Kelly ◽  
Ian A. Critchley ◽  
Mark E. Jones ◽  
Clyde Thornsberry ◽  
...  

ABSTRACT All of the isolates of Staphylococcus aureus (n = 317), Enterococcus species (n = 315), Streptococcus pneumoniae (n = 282), and Staphylococcus epidermidis (n = 176) collected at 16 Canadian microbiology laboratories from October 2000 to April 2001 were susceptible to linezolid. Future studies will determine how linezolid clinical use in Canada affects its in vitro activity.


2006 ◽  
Vol 50 (6) ◽  
pp. 2255-2257 ◽  
Author(s):  
Paul A. Wickman ◽  
Jennifer A. Black ◽  
Ellen Smith Moland ◽  
Kenneth S. Thomson

ABSTRACT The in vitro activity of the novel quinolone DX-619 was compared to those of currently available quinolones against U.S. clinical isolates of Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus spp., Streptococcus pyogenes, and Streptococcus pneumoniae. DX-619 was the most potent quinolone overall, indicating possible utility as an anti-gram-positive quinolone.


Author(s):  
Stephan Kohlhoff ◽  
Margaret R. Hammerschlag

Nafithromycin (13 WCK 4873) is a novel lactone ketolide under clinical development as an orally administrated antibiotic for treatment of community acquired pneumonia (CAP) caused by Streptococcus pneumoniae, Hemophilus influenzae, Moraxella catarrhalis , and methicillin susceptible Staphylococcus aureus .…


Sign in / Sign up

Export Citation Format

Share Document